Желчнокаменная болезнь как коморбидное синдрому поликистозных яичников заболевание

1. Герок В., Блюм Х.Е. Заболевания печени и желчевыделительной системы. Пер. с нем. Под общ. ред. В.Т.Ивашкина, А.А.Шептулина. М.: МЕДпресс-информ, 2009. / Gerok V., Blium Kh.E. Zabolevaniia pecheni i zhelchevydelitel'noi sistemy. Per. s nem. Pod obshch. red. V.T.Ivashkina, A.A.Sheptulina. M.: MEDpress-inform, 2009. [in Russian]
2. Иванченкова Р.А. Хронические заболевания желчевыводящих путей. М.: Атмосфера, 2006. / Ivanchenkova R.A. Khronicheskie zabolevaniia zhelchevyvodiashchikh putei. M.: Atmosfera, 2006. [in Russian]
3. Ильченко А.А. Классификация желчнокаменной болезни. Тер. архив. 2004; 2: 75–9. / Il'chenko A.A. Klassifikatsiia zhelchnokamennoi bolezni. Ter. Arkhiv. 2004; 2: 75–9. [in Russian]
4. Лейшнер У. Практическое руководство по заболеваниям желчных путей. М.: ГЭОТАР-МЕД, 2001. / Leishner U. Prakticheskoe rukovodstvo po zabolevaniiam zhelchnykh putei. M.: GEOTAR-MED, 2001. [in Russian]
5. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии. Под ред. В.Е.Радзинского. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2014. / Rukovodstvo po ambulatorno-poliklinicheskoi pomoshchi v akusherstve i ginekologii. Pod red. V.E.Radzinskogo. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2014. [in Russian]
6. Руководство по репродуктивной медицине. Под ред. Б.Карра, Р.Блэкуэлла, Р.Азиза. Пер. с англ. М.: Практика, 2015. / Rukovodstvo po reproduktivnoi meditsine. Pod red. B.Karra, R.Blekuella, R.Aziza. Per. s angl. M.: Praktika, 2015. [in Russian]
7. Acalovschi M. Cholesterol gallstones: from epidemiology to prevention. Postgrad Med J 2001; 77: 221–9.
8. Acién P, Quereda F, Matallín P et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999; 72: 32–40.
9. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006; 65 (2): 137–45.
10. Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 66 (4): 513–7.
11. Basdevant A. Steroids and lipid metabolism: Mechanism of action. Int J Fertil 1992; 37 (Suppl. 2): 93–7.
12. Bennion, LJ, Grundy SM. Effects of diabetes mellitus on cholesterol metabolism in man. New Eng J Med 1977; 296: 1365–71.
13. Coviello AD, Legro RS, Dunaif A: Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91: 492–7.
14. Cryer A. Comparative biochemistry and physiology of lipoprotein lipase. In: Borensztajn J (ed.) Lipoprotein lipase Evener: Chicago, IL, 1987; p. 277–327.
15. Diehl AK. Cholelithiasis and the insulin resistance syndrome. Hepato­logy 2000; 31: 528–30.
16. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta- analysis. JAMA 2006; 295: 1288–99.
17. Duan LP, Wang HH, Ohashi A, Wang DQ-H. Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects. Am J Physiol Gastrointest Liver Physiol 2006; 290: G269–G276.
18. El-Mazny A, Abou-Salem N, El-Sherbiny W, El-Mazny A. Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2010; 109: 239–41.
19. Freeman R, Pollack R, Rosenbloom E. Assessing impaired glucose tolerance and insulin resistance in Polycystic Ovarian Syndrome with a muffin test: alternative to glucose tolerance test. Endocr Pract 2010; 16 (5): 810–7.
20. Gielkens HA, Lam WF, Coenraad M et al. Effect of insulin on basal and cholecystokinin-stimulated gallbladder motility in humans. J Hepatology 1998; 28: 595–602.
21. Gilat T, Konikoff F. Pregnancy and the biliary tract. Can J Gastroenterol 2000; 14–37.
22. Hahm JS, Park JY, Park KG et al. Gallbladder motility in diabetes mellitus using real time ultrasonography. Am J Gastroenterol 1996; 91: 2391–4.
23. Isik S, Ozcan HN, Ozuguz U et al. Impaired gallbladder motility and the effect of metformin therapy in patients with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012; 76 (3): 373–8; doi: 10.1111/j.1365-2265.2011.04210.x
24. Kline LW, Karpinski E. Progesterone inhibits gallbladder motility through multiple signaling pathways. Steroids 2005; 70 (9): 673–9.
25. Kline LW, Karpinski E. Testosterone and dihydrotestosterone inhibit gallbladder motility through multiple signaling pathways. Steroids 2008; 73: 1174–80.
26. Ko CW, Beresford SA, Schulte SJ. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology 2005; 41 (2): 359–65.
27. Lundholm L, Zang H, Hirschberg AL et al. Key lipogenic gene expression can be decreased by estrogen in human adipose tissue. Fertil Steril 2008; 90: 44–8.
28. Luque-Ramírez M, Alpañés M, Escobar-Morreale HF. The determinants of insulin sensitivity, b-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women who do not have hyperandrogenism. Fertil Steril 2010; 94: 2214–21.
29. Mendez-Sanchez N, Vega, H, Uribe M et al. Risk factors for gallstone disease in Mexicans are similar to those found in Mexican-Americans. Digest Dis Sci 1998; 43: 935–9.
30. Nakeeb A, Comuzzie AG, Al-Azzawi H et al. Insulin resistance causes human gallbladder dysmotility. J Gastrointest Surg 2006; 10: 940–8.
31. Ness GC, Chambers CM. Feedback and hormonalregulation of hepatic3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Proc Soc Exp Biol Med 2000; 224 (1): 8–19.
32. Ness GC, Zhao Z, Wiggins L. Insulin and glucagon modulate hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity by affecting immunoreactive protein levels. J Biol Chem 1994; 269: 29168–72.
33. Pesant MH, Baillargeon JP. Clinically useful predictors of conversion to abnormal glucose tolerance in women with polycystic ovary syndrome. Fertil Steril 2011; 95: 210–5.
34. Philipp BW, Shapiro DJ. Estrogen regulation of hepatic3-hydroxy-3-methylglutaryl coenzyme A reductase and acetyl-CoA carboxylase in xenopus laevis. J Biol Chem 1981; 256 (6): 2922–7.
35. Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology 2000; 31: 299–303.
36. Sacks FM, Walsh BW. The effects of reproductive hormones on serum lipoproteins: Unresolved issues in biology and clinical practice. Multidisciplinary perspectives on menopause. Ann N Y Acad Sci 1990; 592: 272–85.
37. Simon JA, Donald B, Hunninghake MD et al. Effect of Estrogen plus Progestin on Risk for Biliary Tract Surgery in Postmenopausal Women with Coronary Artery Disease: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2001; 135 (7): 493–501.
38. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013; 6: 1–13; doi: 10.2147/CLEP.S37559
39. Strom BL, Tamragouri RN, Morse ML et al. Oral contraceptives and other risk factors for gallbladder disease. Clin Pharmacol Ther 1986; 39: 335–41.
40. Wild RA. The PCO paradigm : sex steroids, lipoprotein lipids, clotting, and the arterial wall. In The Ovary: Regulation, Dysfunction and Treatment. M Filicori and C Flamigni, eds. Elsevier Science B.V., 1996; p. 201–9.

________________________________________________

1. Gerok V., Blium Kh.E. Zabolevaniia pecheni i zhelchevydelitel'noi sistemy. Per. s nem. Pod obshch. red. V.T.Ivashkina, A.A.Sheptulina. M.: MEDpress-inform, 2009. [in Russian]
2. Ivanchenkova R.A. Khronicheskie zabolevaniia zhelchevyvodiashchikh putei. M.: Atmosfera, 2006. [in Russian]
3.  Il'chenko A.A. Klassifikatsiia zhelchnokamennoi bolezni. Ter. Arkhiv. 2004; 2: 75–9. [in Russian]
4. Leishner U. Prakticheskoe rukovodstvo po zabolevaniiam zhelchnykh putei. M.: GEOTAR-MED, 2001. [in Russian]
5. Rukovodstvo po ambulatorno-poliklinicheskoi pomoshchi v akusherstve i ginekologii. Pod red. V.E.Radzinskogo. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2014. [in Russian]
6. Rukovodstvo po reproduktivnoi meditsine. Pod red. B.Karra, R.Blekuella, R.Aziza. Per. s angl. M.: Praktika, 2015. [in Russian]
7. Acalovschi M. Cholesterol gallstones: from epidemiology to prevention. Postgrad Med J 2001; 77: 221–9.
8. Acién P, Quereda F, Matallín P et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999; 72: 32–40.
9. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006; 65 (2): 137–45.
10. Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 66 (4): 513–7.
11. Basdevant A. Steroids and lipid metabolism: Mechanism of action. Int J Fertil 1992; 37 (Suppl. 2): 93–7.
12. Bennion, LJ, Grundy SM. Effects of diabetes mellitus on cholesterol metabolism in man. New Eng J Med 1977; 296: 1365–71.
13. Coviello AD, Legro RS, Dunaif A: Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91: 492–7.
14. Cryer A. Comparative biochemistry and physiology of lipoprotein lipase. In: Borensztajn J (ed.) Lipoprotein lipase Evener: Chicago, IL, 1987; p. 277–327.
15. Diehl AK. Cholelithiasis and the insulin resistance syndrome. Hepato­logy 2000; 31: 528–30.
16. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta- analysis. JAMA 2006; 295: 1288–99.
17. Duan LP, Wang HH, Ohashi A, Wang DQ-H. Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects. Am J Physiol Gastrointest Liver Physiol 2006; 290: G269–G276.
18. El-Mazny A, Abou-Salem N, El-Sherbiny W, El-Mazny A. Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2010; 109: 239–41.
19. Freeman R, Pollack R, Rosenbloom E. Assessing impaired glucose tolerance and insulin resistance in Polycystic Ovarian Syndrome with a muffin test: alternative to glucose tolerance test. Endocr Pract 2010; 16 (5): 810–7.
20. Gielkens HA, Lam WF, Coenraad M et al. Effect of insulin on basal and cholecystokinin-stimulated gallbladder motility in humans. J Hepatology 1998; 28: 595–602.
21. Gilat T, Konikoff F. Pregnancy and the biliary tract. Can J Gastroenterol 2000; 14–37.
22. Hahm JS, Park JY, Park KG et al. Gallbladder motility in diabetes mellitus using real time ultrasonography. Am J Gastroenterol 1996; 91: 2391–4.
23. Isik S, Ozcan HN, Ozuguz U et al. Impaired gallbladder motility and the effect of metformin therapy in patients with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012; 76 (3): 373–8; doi: 10.1111/j.1365-2265.2011.04210.x
24. Kline LW, Karpinski E. Progesterone inhibits gallbladder motility through multiple signaling pathways. Steroids 2005; 70 (9): 673–9.
25. Kline LW, Karpinski E. Testosterone and dihydrotestosterone inhibit gallbladder motility through multiple signaling pathways. Steroids 2008; 73: 1174–80.
26. Ko CW, Beresford SA, Schulte SJ. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology 2005; 41 (2): 359–65.
27. Lundholm L, Zang H, Hirschberg AL et al. Key lipogenic gene expression can be decreased by estrogen in human adipose tissue. Fertil Steril 2008; 90: 44–8.
28. Luque-Ramírez M, Alpañés M, Escobar-Morreale HF. The determinants of insulin sensitivity, b-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women who do not have hyperandrogenism. Fertil Steril 2010; 94: 2214–21.
29. Mendez-Sanchez N, Vega, H, Uribe M et al. Risk factors for gallstone disease in Mexicans are similar to those found in Mexican-Americans. Digest Dis Sci 1998; 43: 935–9.
30. Nakeeb A, Comuzzie AG, Al-Azzawi H et al. Insulin resistance causes human gallbladder dysmotility. J Gastrointest Surg 2006; 10: 940–8.
31. Ness GC, Chambers CM. Feedback and hormonalregulation of hepatic3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Proc Soc Exp Biol Med 2000; 224 (1): 8–19.
32. Ness GC, Zhao Z, Wiggins L. Insulin and glucagon modulate hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity by affecting immunoreactive protein levels. J Biol Chem 1994; 269: 29168–72.
33. Pesant MH, Baillargeon JP. Clinically useful predictors of conversion to abnormal glucose tolerance in women with polycystic ovary syndrome. Fertil Steril 2011; 95: 210–5.
34. Philipp BW, Shapiro DJ. Estrogen regulation of hepatic3-hydroxy-3-methylglutaryl coenzyme A reductase and acetyl-CoA carboxylase in xenopus laevis. J Biol Chem 1981; 256 (6): 2922–7.
35. Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology 2000; 31: 299–303.
36. Sacks FM, Walsh BW. The effects of reproductive hormones on serum lipoproteins: Unresolved issues in biology and clinical practice. Multidisciplinary perspectives on menopause. Ann N Y Acad Sci 1990; 592: 272–85.
37. Simon JA, Donald B, Hunninghake MD et al. Effect of Estrogen plus Progestin on Risk for Biliary Tract Surgery in Postmenopausal Women with Coronary Artery Disease: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2001; 135 (7): 493–501.
38. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013; 6: 1–13; doi: 10.2147/CLEP.S37559
39. Strom BL, Tamragouri RN, Morse ML et al. Oral contraceptives and other risk factors for gallbladder disease. Clin Pharmacol Ther 1986; 39: 335–41.
40. Wild RA. The PCO paradigm : sex steroids, lipoprotein lipids, clotting, and the arterial wall. In The Ovary: Regulation, Dysfunction and Treatment. M Filicori and C Flamigni, eds. Elsevier Science B.V., 1996; p. 201–9.

Ю.Б.Успенская*, И.В.Кузнецова

ГБОУ ВПО Первый Московский государственный университет им. И.М.Сеченова Минздрава России. 
119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*jusp@mail.ru

________________________________________________

Yu.B.Uspenskaya*, I.V.Kuznetsova

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 
119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*jusp@mail.ru